Drug intelligence / Profile preview

zanubrutinib

Development stage: Approved
Lead developer: BeiGene
Modality: Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Fragment-Derived Small Molecules → Multivalent & Scaffold-Based Small Molecules → Small Molecules
Administration: Oral

Overview

Zanubrutinib is a second-generation, highly selective, irreversible small molecule inhibitor of Bruton's tyrosine kinase (BTK). It is designed to maximize BTK occupancy and minimize off-target kinase inhibition. By inhibiting BTK, zanubrutinib disrupts B-cell receptor signaling pathways that are critical for the survival and proliferation of malignant B cells. This mechanism underlies its efficacy in treating various B-cell malignancies. Zanubrutinib was developed by BeiGene and is marketed under the brand name Brukinsa (百悦泽). It was first approved in the United States in November 2019 for mantle cell lymphoma (MCL) after at least one prior therapy, making it the first Chinese-developed cancer drug approved by the FDA. Subsequent approvals include Waldenström macroglobulinemia (WM), marginal zone lymphoma (MZL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma (FL) in combination with obinutuzumab[3][7][9][10]. Clinical trials have demonstrated superior efficacy and improved safety/tolerability compared to first-generation BTK inhibitors such as ibrutinib[6][8].

Brand names: Brukinsa百悦泽
Other names: 泽布替尼赞鲁替尼澤佈替尼

Targets

BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on zanubrutinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zanubrutinib.

Explore the full profile